Krishant Deo completed his PhD in Medicinal Chemistry at Western Sydney University. He then went on to join ANSTO as a Radiochemist, where he worked across commercial and research projects, contributing to the development of both therapeutic and diagnostic radiopharmaceuticals, and medical devices.
His expertise includes manual and automated radiolabelling techniques, with a strong emphasis on method optimisation to enhance process efficiency and reproducibility. Currently based at the University of Sydney’s Brain and Mind Centre (BMC), Krishant is leading initiatives to expand the BMCs radiochemistry platform by enhancing infrastructure, streamlining workflows and supporting collaborative research across multiple disciplines.
He aims to facilitate the transition of radiopharmaceuticals from research to preclinical and clinical applications, supporting advancements in diagnostic imaging within nuclear medicine.
Research at the facility is improving patient outcomes by setting new standards for ultra-low dose imaging, which could shape radiation safety guidelines for pregnancy, paediatric and oncology imaging
18 June 2025
Donanemab, developed by Lilly, is the first disease-modifying treatment for early-stage Alzheimer’s disease to be approved for use in Australia. The National Imaging Facility supported its developme
16 June 2025
The Australian National Total Body PET Facility, launched just over a year ago, has shown that sharing PET infrastructure has proved to be a cost-effective model – bringing benefits to both patient
03 June 2025
Dr Sicong Tu is excited about helping motor neurone disease (MND) patients gain a much better idea of their disease progression: “The focus of our network is on bridging the gap between leading Aust
28 May 2025